Vestipitant

Vestipitant
Systematic (IUPAC) name
	(2S)-N-[(1R)-1-[3,5-bis(trifluoromethyl)phenyl]ethyl]-2-(4-fluoro-2-methylphenyl)-N-methylpiperazine-1-carboxamide
Clinical data
Pregnancy cat.	?
Legal status	?
Identifiers
CAS number	334476-64-1
ATC code	None
PubChem	CID 9832383
UNII	S052TOI9BI
ChEMBL	CHEMBL522987
Chemical data
Formula	C23H21F10N3O
Mol. mass	545.416 g/mol
	SMILES FC(F)(F)c1cc(F)ccc1C2CNCCN2C(=O)N(C)C(C)c3cc(C(F)(F)F)cc(c3)C(F)(F)F;
(what is this?) (verify);

Vestipitant is a drug developed by GlaxoSmithKline which acts as a selective antagonist for the NK₁ receptor. It is under development as a potential antiemetic and anxiolytic drug,^[1]^[2] and as a treatment for tinnitus.^[3]

References [edit]

^ Reddy, GK; Gralla, RJ; Hesketh, PJ (2006). "Novel neurokinin-1 antagonists as antiemetics for the treatment of chemotherapy-induced emesis". Supportive cancer therapy 3 (3): 140–2. doi:10.3816/SCT.2006.n.011. PMID 18632487.
^ Brocco, M; Dekeyne, A; Mannoury La Cour, C; Touzard, M; Girardon, S; Veiga, S; De Nanteuil, G; Dejong, TR et al. (2008). "Cellular and behavioural profile of the novel, selective neurokinin1 receptor antagonist, vestipitant: a comparison to other agents". European neuropsychopharmacology : the journal of the European College of Neuropsychopharmacology 18 (10): 729–50. doi:10.1016/j.euroneuro.2008.06.002. PMID 18657401. |displayauthors= suggested (help)
^ ClinicalTrials.gov NCT00394056 Vestipitant Or Vestipitant/Paroxetine Combination In Subjects With Tinnitus And Hearing Loss

This drug article relating to the gastrointestinal system is a stub. You can help Wikipedia by expanding it.

This drug article relating to the nervous system is a stub. You can help Wikipedia by expanding it.